VPN Plus+ ExclusiveLess Fear, More Hope: How Research is Driving New Strategies in Hemangiosarcoma Treatment and PreventionDecember 11, 2025In this session: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, enlightens attendees with original research from the University of Minnesota on eBAT, a first-in-class bispecific targeted angiotoxin. eBAT is designed to selectively eliminate tumor cells and tumor-initiating cells, offering dual potential as both a therapeutic and preventive option in high-risk canine populations.
Education Center - SponsoredWhere next for point-of-care diagnostics?by • Zoetis Diagnostics USPoint-of-care diagnostics are rapidly evolving. Complete blood counts and cytology evaluations are no longer confined to reference laboratories – veterinarians can now run these tests in clinic, with artificial intelligence-powered tools. This shift is bringing expert-level care to general practice, streamlining workflows and driving better patient care. Hear from Zoetis leaders on how point-of-care diagnostic technologies are transforming veterinary practice, helping to empower teams, broaden access to care, and improving patient outcomes.
